Human papillomavirus (HPV) infections are the most common sexually transmitted virus worldwide. While most infections self-resolve, persistent infections can result in cervical cancer as well as in anal, oropharyngeal and other HPV-associated cancers. However, current HPV tests cannot differentiate precancerous lesions from clinically insignificant infection.

Overexpression of HPV E6 and E7 oncoproteins is associated with persistent HPV infection and disease progression toward precancers and cancers. Initial results, based on 158 cases with known histology results, showed that E6/E7 overexpression is more likely detected in women with biopsy-proven CIN2+ and CIN3+ disease. The odds-ratio analysis showed that women with E6/E7 positive results have an 8-fold higher risk of having CIN3 than women who test negative for E6/E7 (p=0.01).  

The power to differentiate disease from clinically insignificant infections

Detecting E6/E7 overexpression in high-risk HPV types

OncoHealth’s proprietary pan anti-E6 and pan anti-E7 mouse monoclonal antibodies bind to E6 and E7 oncoproteins from 14 high-risk HPV types that are associated with higher risk of developing cervical neoplasia.
For the detection of HPV E6 and E7 oncoproteins in liquid-based cytology samples

Now available: Two convenient formats for the qualitative detection of HPV E6/E7 oncoproteins in the nucleus and cytoplasm of cervical cells collected in liquid-based cytology (LBC) samples

- The Direct E6/E7® Whole-Cell ELISA™ detects nuclear and cytoplasmic E6 and E7 oncoproteins in a simple, easy-to-use 96-well format4,5
  - Whole-cell analysis: no lysis, no extraction required
  - E6 and E7 oncoprotein detection with anti-E6 and anti-E7 biotinylated antibody cocktail
  - Colorimetric detection (OD450); HRP-streptavidin reagent
- The Direct E6/E7® Flow assay provides single-cell analysis of epithelial cells and the ability to discriminate between E6 and E7
  - Detect E6 and E7 oncoproteins in fixed samples by FITC-anti-E6 and PE-anti-E7 antibody using a flow cytometer

To place an order or to be referred to a local distributor, call +1 408-577-1389, email orders@oncohealthcorp.com or fax +1 708-778-8571

---

<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Product Description</th>
</tr>
</thead>
</table>
| OH-200 | OncoHealth DIRECT E6/E7® HPV Whole-Cell ELISA™
| OH-220 | OncoHealth DIRECT E6/E7® HPV Flow Assay
| OH-230 | OncoHealth DIRECT E6/E7® HPV Flow Assay


For research use only. Not for use in diagnostic procedures.

U.S. Patent Nos. 7,732,166, 7,972,776, 8,278,056. Direct E6E7 is a registered trademark, and OncoHealth and OncoHealth logo are trademarks of OncoHealth Corporation. All other trademarks and brands are the property of their respective owners.

© 2013 OncoHealth Corporation